share_log

藥明生物：根據受限制股份獎勵計劃授出受限制股份

WUXI BIO: GRANT OF RESTRICTED SHARES UNDER RESTRICTED SHARE AWARD SCHEME

香港交易所 ·  Mar 27 07:58
Summary by Moomoo AI
药明生物於2024年3月27日宣布，根據其受限制股份獎勵計劃，已批准授出總計19,372,191股受限制股份給予陳博士、周博士以及本集團1,892名員工。該批受限制股份的20%將於授出後的第二、第三及第四週年當日歸屬，餘下40%將於第五週年當日歸屬。該授出行為旨在激勵員工提升表現及效率，並無附帶業績目標。此外，該授出不需獲得股東批准，且不會導致向個別承授人授出的股份超過已發行股份的1%。董事會認為此舉符合公司及股東整體利益，並於授出後仍有208,842,061股受限制股份可供日後授出。
药明生物於2024年3月27日宣布，根據其受限制股份獎勵計劃，已批准授出總計19,372,191股受限制股份給予陳博士、周博士以及本集團1,892名員工。該批受限制股份的20%將於授出後的第二、第三及第四週年當日歸屬，餘下40%將於第五週年當日歸屬。該授出行為旨在激勵員工提升表現及效率，並無附帶業績目標。此外，該授出不需獲得股東批准，且不會導致向個別承授人授出的股份超過已發行股份的1%。董事會認為此舉符合公司及股東整體利益，並於授出後仍有208,842,061股受限制股份可供日後授出。
Pharmaceutical Biologics announced on 27 March 2024 that it has approved the grant of a total of 19,372,191 shares of restricted shares to Dr. Chan, Dr. Zhou and 1,892 employees of the Group under its Restricted Share Award Scheme. 20% of the restricted shares will be vested on the dates of the second, third and fourth years after the grant, and the remaining 40% will be vested on the date of the fifth anniversary. The awarding act is designed to motivate employees to improve performance and efficiency without a performance target. In addition, the grant is not subject to shareholder approval and will not result in shares granted to individual grantors exceeding 1% of the issued shares. The Board of Directors considers this move to be in the overall interests of the Company and its shareholders and has 208,842,061 shares of restricted stock available for future issuance following the grant.
Pharmaceutical Biologics announced on 27 March 2024 that it has approved the grant of a total of 19,372,191 shares of restricted shares to Dr. Chan, Dr. Zhou and 1,892 employees of the Group under its Restricted Share Award Scheme. 20% of the restricted shares will be vested on the dates of the second, third and fourth years after the grant, and the remaining 40% will be vested on the date of the fifth anniversary. The awarding act is designed to motivate employees to improve performance and efficiency without a performance target. In addition, the grant is not subject to shareholder approval and will not result in shares granted to individual grantors exceeding 1% of the issued shares. The Board of Directors considers this move to be in the overall interests of the Company and its shareholders and has 208,842,061 shares of restricted stock available for future issuance following the grant.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more